Imaging, Diagnosis, Prognosis Early [F]Fluorodeoxyglucose Positron Emission Tomography at Two Days of Gefitinib Treatment Predicts Clinical Outcome in Patients with Adenocarcinoma of the Lung
نویسندگان
چکیده
Purpose: Positron emission tomography (PET) with [F]fluorodeoxyglucose (FDG) is increasingly used in early assessment of tumor response after chemotherapy. We investigated whether a change in [F]FDG uptake at 2 days of gefitinib treatment predicts outcome in patients with lung adenocarcinoma. Experimental Design: Twenty patients were enrolled. [F]FDG-PET/computed tomographic (CT) scan was carried out before and 2 days after gefitinib treatment. Maximum standardized uptake values (SUV) were measured, and post-gefitinib percentage changes in SUV were calculated. Early metabolic response (SUV decline < 25%) was compared with morphologic response evaluated by CT scan and with progression-free survival (PFS). Results: At 2 days of gefitinib treatment, 10 patients (50%) showedmetabolic response, 8 hadmetabolic stable disease, and 2 had progressivemetabolic disease. Percentage changes of SUV at 2 days were correlated with those of tumor size inCT at 1month (R1⁄40.496;P1⁄4 0.0008).EGFR genewas assessable in 15 patients, and of 12 patients with EGFRmutations, 8 showedmetabolic response at 2 days and 6 showedmorphologic response at 1 month. None of 3 patients with wild-type EGFR showedmetabolic or morphologic response. Metabolic response at 2 days was not statistically associatedwith PFS (P1⁄4 0.095), but when a cutoff value of 20% in SUV decline was used, metabolic responders had longer PFS (P < 0.0001). Conclusion: Early assessment of [F]FDG tumor uptake with PET at 2 days of gefitinib treatment could be useful to predict clinical outcome earlier than conventional CT evaluation in patients with lung adenocarcinoma. Clin Cancer Res; 18(1); 220–8. 2011 AACR.
منابع مشابه
Early [18F]fluorodeoxyglucose positron emission tomography at two days of gefitinib treatment predicts clinical outcome in patients with adenocarcinoma of the lung.
PURPOSE Positron emission tomography (PET) with [(18)F]fluorodeoxyglucose (FDG) is increasingly used in early assessment of tumor response after chemotherapy. We investigated whether a change in [(18)F]FDG uptake at 2 days of gefitinib treatment predicts outcome in patients with lung adenocarcinoma. EXPERIMENTAL DESIGN Twenty patients were enrolled. [(18)F]FDG-PET/computed tomographic (CT) sc...
متن کاملPredictive ability of 18F-fluorodeoxyglucose positron emission tomography/computed tomography for pathological complete response and prognosis after neoadjuvant chemotherapy in triple-negative breast cancer patients
Objective The mortality of patients with locally advanced triple-negative breast cancer (TNBC) is high, and pathological complete response (pCR) to neoadjuvant chemotherapy (NAC) is associated with improved prognosis. This retrospective study was designed and powered to investigate the ability of 18F-fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) to predict pat...
متن کاملMetastatic Adenocarcinoma of Temporal Bone with Collet-Sicard Syndrome
Introduction: Metastatic tumors of the temporal bone are extremely rare. Collet-Sicard syndrome is an uncommon condition characterized by unilateral palsy of the lower four cranial nerves. The clinical features of temporal bone metastasis are nonspecific and mimic infections such as chronic otitis media and mastoiditis. Case Report: This report describes a rare case of metastatic adenocarcino...
متن کاملThe Efficiency of Respiratory-gated 18F-FDG PET/CT in Lung Adenocarcinoma: Amplitude-gating Versus Phase-gating Methods
Objective(s): In positron emission tomography (PET) studies, thoracic movement under free-breathing conditions is a cause of image degradation. Respiratory gating (RG) is commonly used to solve this problem. Two different methods, i.e., phase-gating (PG) and amplitude-gating (AG) PET, are available for respiratory gating. It is important to know the strengths and weaknesses of both methods when...
متن کامل[18F]Fluorothymidine positron emission tomography before and 7 days after gefitinib treatment predicts response in patients with advanced adenocarcinoma of the lung.
PURPOSE To evaluate the usefulness of 3'-deoxy-3'-[18F]fluorothymidine (FLT)-positron emission tomography (PET) for predicting response and patient outcome of gefitinib therapy in patients with adenocarcinoma of the lung. EXPERIMENTAL DESIGN Nonsmokers with advanced or recurrent adenocarcinoma of the lung were eligible. FLT-PET images of the thorax were obtained before and 7 days after the st...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
دوره شماره
صفحات -
تاریخ انتشار 2011